Small molecule inhibitors reveal an indispensable scaffolding role of RIPK2 in NOD2 signaling

  • EMBO J. 2018 Sep 3;37(17):e99372. doi: 10.15252/embj.201899372.
Matous Hrdinka  1 ,  Lisa Schlicher  1 ,  Bing Dai  2 ,  Daniel M Pinkas  3 ,  Joshua C Bufton  3 ,  Sarah Picaud  3 ,  Jennifer A Ward  3  4 ,  Catherine Rogers  3  4 ,  Chalada Suebsuwong  5 ,  Sameer Nikhar  6 ,  Gregory D Cuny  6 ,  Kilian Vm Huber  3  4 ,  Panagis Filippakopoulos  3 ,  Alex N Bullock  3 ,  Alexei Degterev  7 ,  Mads Gyrd-Hansen  8
Affiliations
  • 1. Nuffield Department of Clinical Medicine, Ludwig Institute for Cancer Research, University of Oxford, Oxford, UK.
  • 2. Department of Developmental, Molecular & Chemical Biology, Tufts University School of Medicine, Boston, MA, USA.
  • 3. Nuffield Department of Clinical Medicine, Structural Genomics Consortium, University of Oxford, Oxford, UK.
  • 4. Nuffield Department of Clinical Medicine, Target Discovery Institute, University of Oxford, Oxford, UK.
  • 5. Department of Chemistry, University of Houston, Houston, TX, USA.
  • 6. Department of Pharmacological and Pharmaceutical Sciences, University of Houston, Houston, TX, USA.
  • 7. Department of Developmental, Molecular & Chemical Biology, Tufts University School of Medicine, Boston, MA, USA [email protected] [email protected].
  • 8. Nuffield Department of Clinical Medicine, Ludwig Institute for Cancer Research, University of Oxford, Oxford, UK [email protected] [email protected].
Abstract

RIPK2 mediates inflammatory signaling by the bacteria-sensing receptors NOD1 and NOD2. Kinase inhibitors targeting RIPK2 are a proposed strategy to ameliorate NOD-mediated pathologies. Here, we reveal that RIPK2 kinase activity is dispensable for NOD2 inflammatory signaling and show that RIPK2 inhibitors function instead by antagonizing XIAP-binding and XIAP-mediated ubiquitination of RIPK2. We map the XIAP binding site on RIPK2 to the loop between β2 and β3 of the N-lobe of the kinase, which is in close proximity to the ATP-binding pocket. Through characterization of a new series of ATP pocket-binding RIPK2 inhibitors, we identify the molecular features that determine their inhibition of both the RIPK2-XIAP interaction, and of cellular and in vivoNOD2 signaling. Our study exemplifies how targeting of the ATP-binding pocket in RIPK2 can be exploited to interfere with the RIPK2-XIAP interaction for modulation of NOD signaling.

Keywords
XIAP; NOD2 signaling; RIPK2; kinase inhibitor; ubiquitin.
Products